Products and Pipeline
Partners and distributors
Press releases 2011
Press releases 2010
Press releases 2009
Press releases 2008
Press releases 2007
Press releases 2011
- 2011 -
MOBERG DERMA TERMINATES COLLABORATION IN CANADA
Moberg Derma AB (STO: MOB) and Medical Futures Inc. have agreed that the distribution agreement between the parties shall cease, and that cooperation ends. The agreement gave the distributor the exclusive right to market and sell Emtrix® in Canada.
MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT
Moberg Derma AB (publ.) and Meda have entered into an additional license agreement for Nalox™ - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. The agreement extends Meda's rights to market and sell Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg Derma assumes production and supply responsibility.
MOBERG DERMA IS GRANTED MSEK 4 FOR LIMTOP
Moberg Derma AB (OMX: MOB) has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer. The goal of the Vinnova funding is that small and medium-sized enterprises will increase their competitiveness and growth by investing in research and development and thus contribute to growth in Sweden.
MOBERG DERMA DISCONTINUES PRECLINICAL DEVELOPMENT PROGRAM FOR A-FIZZ
Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the company’s criteria.
MOBERG DERMA NOMINATION COMMITTEE APPOINTED
In accordance with the decision taken at Moberg Derma’s Annual General Meeting 2011 the Chairman of the Board has contacted the largest shareholders of the company to appoint a Nomination Committee before the Annual General Meeting 2012.
MOBERG DERMA AND MEDA SIGN AGREEMENT FOR NALOX IN EUROPE
Moberg Derma AB (OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Meda is granted exclusive rights to market and sell Nalox® in a large number of countries in Europe. Moberg Derma assumes production and supply responsibility. Over the past year, Meda has made Nalox® market leader in the Nordic region.
MOBERG DERMA HAS COMPLETED RECRUITMENT FOR MOB-015 PHASE II CLINICAL STUDY
Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study. MOB-015 is the company’s second-generation topical treatment for nail fungus.
FIRST ORDER FROM WALMART IN USA
The public company Moberg Derma AB (publ.) has through its U.S. distributor Alterna LLC received a first order from the world’s largest retail chain, Walmart, for Emtrix® – its treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Emtrix® will be marketed under Alterna’s well established foot care brand Kerasal® and will be named Kerasal® Nail.
MOBERG DERMA AND ALTERNA SIGNS DISTRIBUTION AGREEMENT FOR USA
Moberg Derma AB (publ.) and Alterna LLC have entered into a distribution and cooperation agreement for Emtrix® – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Alterna receives exclusive rights to sell Emtrix® in the U.S. and assumes responsibility for sales and marketing activities. Moberg Derma assumes production and supply responsibility. The agreement also includes co-funding of marketing activities and a net income-sharing mechanism.
INCREASED NUMBER OF SHARES AND VOTES IN MOBERG DERMA
The number of shares and the number of votes in Moberg Derma AB (publ) have changed as a result of a new issue of 2,550,524 shares in total, in connection with Moberg Derma's listing on NASDAQ OMX Stockholm.
MOBERG DERMA OBTAINS APPROVAL FOR TREATMENT FOR ATOPIC ECZEMA AND DRY SKIN
Moberg Derma AB (publ.) today announced that CE mark has been granted for Kaprolac Skin Repair & Hydration, a product designed to treat atopic eczema and dry skin. This CE mark provides authorization to market and sell the product in the EU/EEA.
MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEALAND
Moberg Derma AB (publ.) has entered into a distribution agreement with OzHealth Pharma for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement OzHealth Pharma is granted exclusive rights to market and sell Emtrix® in Australia and New Zealand.
MOBERG DERMA’S PUBLIC OFFER OVERSUBSCRIBED – trading on the NASDAQ OMX Stockholm will start on 26 May
The public offer to acquire shares in Moberg Derma AB (publ) attracted large interest and the offer was oversubscribed. Through this new share issue Moberg Derma has raised SEK 74 million before issue expenses. May 26th, 2011 will be the first day of trading on the main market of NASDAQ OMX Stockholm (Ticker symbol: MOB). The Board of Moberg Derma has taken a decision on the allotment of shares.
MOBERG DERMA TO LIST ON NASDAQ OMX STOCKHOLM - A different kind of pharmaceutical company that focuses on topical products
The Board of Directors of Moberg Derma AB (publ) has applied for a listing of its shares on NASDAQ OMX Stockholm, the main list. In connection with the listing, Moberg Derma will broaden its ownership base through a new issue of SEK 74m.
PETER ROTHSCHILD ELECTED TO MOBERG DERMA BOARD
On April 18, 2011 was the Annual General Meeting of Moberg Derma AB (publ). In all suggestions the meeting decided in accordance with the proposal.
MOBERG DERMA SIGNS LETTER OF INTENT FOR DISTRIBUTION IN THE UNITED STATES
Moberg Derma AB (publ) has entered into a letter of intent for distribution in the United States. The letter of intent includes Emtrix® – a product for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. The intention is to give the distributor an exclusive right to market and sell Emtrix® in the U.S.
MOBERG DERMA RIGHTS ISSUE FULLY SUBSCRIBED
Moberg Derma AB (publ) has completed the rights issue to existing shareholders decided on 24 February 2011. The new issue provides the company with MSEK 12.0.
MOBERG DERMA SIGNS DISTRIBUTION AGREEMENTS IN SPAIN AND UK
Moberg Derma AB (publ) has entered into distribution agreements with AG Farma S.A. in Spain and HairXpertise Ltd in UK for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. Under the agreements, the distributors are granted exclusive rights to market and sell Emtrix®.
MOBERG DERMA REPORTS POSITIVE CLINICAL RESULTS FOR EMTRIX
Moberg Derma AB today reports positive results from a clinical trial of Emtrix. The trial included 75 patients with nail fungus (onychomycosis) and the results showed that 92% of the patients improved after 8 weeks of treatment. Already after 2 weeks, 77% of the patients were improved.
Subscribe to information on Moberg Pharma
Contact Investor relations:
Magnus Persson, IR
Phone: +46 733 55 26 01
Peter Wolpert, CEO
Phone +46 8 522 307 00
Moberg Pharma AB (publ)
Gustavslundsvägen 42, 5 tr, SE-167 51 Bromma, Sweden
Phone: +46 8 522 30 700
© Moberg Pharma AB 2013